Health Canada Licence: 98903, Device class: 3 

IBDoc^® is not available for sale in the US.

IBDoc^®  Highlights

Learn more about this calprotectin home test and check out the IBDoc^®  highlights including key features, studies, posters, citations, videos, informational flyers and more!

Three Easy Steps to Help Monitor IBD

IBDoc^® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. Based on BÜHLMANN’s long lasting experience with calprotectin assays, IBDoc^®  allows IBD patients for convenient self-testing of fecal calprotectin. CALEX® Valve has been developed for simple and easy-to-handle stool extraction. The incorporated valve allows the precise application of 60 µl onto the test cassette. The CalApp^®  smart phone application is available for  iOS and Android transforms smartphones into a test cassette reader.

Features:

• Reliable: All components of the IBDoc^® systems have been developed to measure up to the highest standards of the industry resulting in a robust, reliable test – the first of its kind.  Quality is not just a statement, but part of BÜHLMANN’s daily commitment.

• Easy to Use: The IBDoc^® Test Kit provides an easy to use therapy monitoring home testing system for IBD Patients – empowering the patients, connecting them with their doctors and allowing them to manage the disease as a team.

• Secure: BÜHLMANN takes great care that patient information is transmitted and stored in a secure way. The IBDoc^® Portal works with online-banking grade data encryption and only a patient’s treating physician has access to medical information.

 IBDoc^® Canadian User Performance Evaluation

Learn more about BÜHLMANN’s IBDoc^® in this Canadian user performance evaluation publication.  View the results of  the usability assessment from the study participants of this fecal calprotectin home test.

Highlights from this Publication

“This study shows that patients with IBD found the home-based FC monitoring kit IBDoc to be user friendly. The majority of patients found it easy-to-use and felt that most patients would be able to learn how to use it quickly without the support of an assisting person. Eighty-five percent of patients agreed to use the IBDoc in the future…In this study, we demonstrate that patients are able to use the home-based IBDoc to measure their FC, providing accurate results and thereby improving patient compliance. If used by patients outside a clinical trial setting, it shows promise to improve patient IBD care.”

New Faecal Calprotectin Cut-off Points for Remission and Active Disease Defined by UCEIS and Nancy Indices in Ulcerative Colitis (UC)

Check out this interesting poster focusing on disease activity assessment in the management of UC using IBDoc^® to measure fecal calprotectin (Fcal)  to compare the values with that of simple clinical colitis activity index (SCCAI) and endoscopic/histopathological activity (UCEIS and Nancy indices).

Highlights from this Poster

“Conclusions:

An FCal <180 g/g is indicative of endoscopic and histological remission. FCal may act as a reliable marker of mucosal healing, replacing the need for endoscopy in some patients.”